Advertisement

Topics

Sanofi and Principia join forces to advance potential MS therapy

04:00 EST 10 Nov 2017 | EPM Magazine

Sanofi and Principia Biopharma have entered into an agreement to develop a clinical-stage oral drug candidate as a potential therapy for multiple sclerosis (MS) and other central nervous system (CNS) diseases.

Original Article: Sanofi and Principia join forces to advance potential MS therapy

NEXT ARTICLE

More From BioPortfolio on "Sanofi and Principia join forces to advance potential MS therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...